300558 Stock Overview
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Betta Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥41.73 |
| 52 Week High | CN¥73.11 |
| 52 Week Low | CN¥33.11 |
| Beta | 0.71 |
| 1 Month Change | 3.73% |
| 3 Month Change | 15.31% |
| 1 Year Change | -37.34% |
| 3 Year Change | -57.77% |
| 5 Year Change | 3.81% |
| Change since IPO | 64.94% |
Recent News & Updates
Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem
Apr 26
Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts
Apr 23Shareholder Returns
| 300558 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.9% | 2.7% | 1.2% |
| 1Y | -37.3% | -10.9% | -12.6% |
Return vs Industry: 300558 underperformed the CN Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: 300558 underperformed the CN Market which returned -13.2% over the past year.
Price Volatility
| 300558 volatility | |
|---|---|
| 300558 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 300558 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300558's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,000 | Lieming Ding | www.bettapharma.com |
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is headquartered in Hangzhou, China.
Betta Pharmaceuticals Co., Ltd. Fundamentals Summary
| 300558 fundamental statistics | |
|---|---|
| Market cap | CN¥17.46b |
| Earnings (TTM) | CN¥394.78m |
| Revenue (TTM) | CN¥2.66b |
44.2x
P/E Ratio6.6x
P/S RatioIs 300558 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300558 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.66b |
| Cost of Revenue | CN¥454.77m |
| Gross Profit | CN¥2.21b |
| Other Expenses | CN¥1.81b |
| Earnings | CN¥394.78m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 0.94 |
| Gross Margin | 82.91% |
| Net Profit Margin | 14.84% |
| Debt/Equity Ratio | 44.2% |
How did 300558 perform over the long term?
See historical performance and comparison